<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04934410</url>
  </required_header>
  <id_info>
    <org_study_id>S-602/2020</org_study_id>
    <nct_id>NCT04934410</nct_id>
  </id_info>
  <brief_title>Induction Agent and Incidence of Hypotension in Heart Failure Patients Undergoing LVAD-Implantation</brief_title>
  <acronym>INTENS</acronym>
  <official_title>Induction Agent and Incidence of Hypotension in Heart Failure Patients Undergoing LVAD-Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      The induction of anesthesia is one of the most critical situations for high-risk-patients&#xD;
      undergoing major surgery. For several reasons, it is crucial to maintain adequate blood&#xD;
      pressure and cardiac output during this phase.&#xD;
&#xD;
      This observational study aims to find out if the choice of the induction agent has a major&#xD;
      impact on blood pressure and the use of antihypotensive drugs during the induction and the&#xD;
      surgical procedure in heart-failure patients undergoing the implantation of a left&#xD;
      ventricular assist device (LVAD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Post-Induction hypotension</measure>
    <time_frame>First 30 minutes after induction of anesthesia</time_frame>
    <description>The incidence of hypotension in the first 30 minutes after the induction of anesthesia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antihypotensive drugs after induction</measure>
    <time_frame>First 30 minutes after induction of anesthesia</time_frame>
    <description>Use of antihypotensive drugs during the first 30 minutes after induction of anesthesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antihypotensive drugs during the procedure</measure>
    <time_frame>Begin of the procedure until end of the procedure</time_frame>
    <description>Use of antihypotensive drugs during the procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay on the intensive care unit (ICU)</measure>
    <time_frame>After the procedure and transport to intensive care unit, total time in hours until submission from I. Expected time frame is 48 to 96 hours.CU</time_frame>
    <description>The time the patient has to be treated on intensive care unit after the procedure (in hours) before submission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delirium</measure>
    <time_frame>First 24 hours after the end of the procedure</time_frame>
    <description>Diagnosis of postoperative delirium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney</measure>
    <time_frame>First 28 days after procedure</time_frame>
    <description>Occurrence of acute kidney failure as defined by Kidney Disease: Improving Global Outcomes (KDIGO)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>First 28 days after procedure</time_frame>
    <description>Mortalitiy in the first 28 days after the procedure</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Blood Pressure, Low</condition>
  <arm_group>
    <arm_group_label>Patients undergoing Implantation of left ventricular assist device (Etomidate)</arm_group_label>
    <description>High-risk heart-failure patients undergoing the implantation of a left ventricular assist device (LVAD). The induction agent is etomidate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients undergoing Implantation of left ventricular assist device (Midazolam)</arm_group_label>
    <description>High-risk heart-failure patients undergoing the implantation of a left ventricular assist device (LVAD). The induction agent is midazolam.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients undergoing Implantation of left ventricular assist device (Sevoflurane)</arm_group_label>
    <description>High-risk heart-failure patients undergoing the implantation of a left ventricular assist device (LVAD). The induction agent is sevoflurane.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etomidate</intervention_name>
    <description>Use of etomidate during induction as decided by attending anesthesiologist</description>
    <arm_group_label>Patients undergoing Implantation of left ventricular assist device (Etomidate)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Use of midazolam during induction as decided by attending anesthesiologist</description>
    <arm_group_label>Patients undergoing Implantation of left ventricular assist device (Midazolam)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>Use of sevoflurane during induction as decided by attending anesthesiologist</description>
    <arm_group_label>Patients undergoing Implantation of left ventricular assist device (Sevoflurane)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with terminal heart failure which are scheduled for implantation of a left&#xD;
        ventricular assist device (LVAD)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Heart failure patients scheduled for implantation of left ventricular assist device&#xD;
        (LVAD)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Presence of another cardiac assist device in the patient (for example ECLS)&#xD;
&#xD;
          -  No consent of the patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian E Stephan, MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Anesthesiology, Heidelberg University Hospital, Heidelberg, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adrian E Stephan, MD</last_name>
    <phone>004962215636107</phone>
    <email>adrian.stephan@med.uni-heidelberg.de</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 29, 2021</study_first_submitted>
  <study_first_submitted_qc>June 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2021</study_first_posted>
  <last_update_submitted>October 17, 2021</last_update_submitted>
  <last_update_submitted_qc>October 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heidelberg University</investigator_affiliation>
    <investigator_full_name>Dr. Adrian Stephan</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Blood Pressure</keyword>
  <keyword>Catecholamines</keyword>
  <keyword>Heart failure</keyword>
  <keyword>High risk patients</keyword>
  <keyword>Left ventricular assist device</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Etomidate</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

